KMKenichi Makishima

Kenichi Makishima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenichi Makishima has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discordant lymphoma consisting of splenic marginal zone lymphoma and diffuse large B-cell lymphoma in a hepatitis B virus carrier suggests virus-associated lymphomagenesis

    by Takumi Kaieda, Kenichi Makishima, Sakurako Suma, Yuya Sasaki, Yasuhito Suehara, Hajime Yasuda, Ryota Matsuoka, Fumiaki Matsumura, Tatsuhiro Sakamoto, Keiichiro Hattori, et al.

    Discordant lymphoma (DL) is a rare entity characterized by the synchronous occurrence of two distinct lymphoma subtypes in different anatomical sites. While some DLs reflect transformation from a common progenitor, others may arise from genetically unrelated clones. Clarifying the clonal relationship is critical to understanding DL pathogenesis. Whole-exome sequencing (WES) and B-cell receptor (BCR) repertoire analysis offer valuable insights, but comprehensive genomic studies in DL remain limited. We present a 61-year-old male with hepatitis B surface antigen (HBsAg) positivity, diagnosed with SMZL from splenectomy and diffuse large B-cell lymphoma (DLBCL) from mesenteric lymph node biopsy. He achieved complete remission after R-CHOP and later relapsed with DLBCL in the cervical lymph nodes. Whole-exome sequencing revealed no shared somatic mutations between SMZL and DLBCL. BCR repertoire analysis also demonstrated distinct V-J gene usage, and cytogenetic analyses supported their independent origins. Notably, DLBCL harbored mutations in TP53, MTOR, and BCL6 rearrangement alterations previously associated with hepatitis B virus (HBV)-associated lymphomas. Our multi-platform analysis supports the clonal independence of SMZL and DLBCL in this patient, suggesting that these two lymphomas arose independently despite developing concurrently. Chronic antigen stimulation and genomic integration from HBV may have contributed to dual lymphomagenesis through separate pathways. This case illustrates the potential role of HBV in driving distinct yet simultaneous B-cell neoplasms.

  • Open Access

    Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes

    by Yasuhito Suehara, Kana Sakamoto, Manabu Fujisawa, Kota Fukumoto, Yoshiaki Abe, Kenichi Makishima, Sakurako Suma, Tatsuhiro Sakamoto, Keiichiro Hattori, Takeshi Sugio, et al.

    Peripheral T-cell lymphoma (PTCL) exhibits a diverse clinical spectrum, necessitating methods to categorize patients based on genomic abnormalities or tumor microenvironment (TME) profiles. We conducted an integrative multiomics study in 129 PTCL patients, performing whole-exome sequencing and identifying three genetic subtypes: C1, C2, and C3. C2 was characterized by loss of tumor suppressor genes and chromosomal instability, while C1 and C3 shared T follicular helper (TFH)-related genomic alterations, with C3 also showing a high incidence of IDH2 mutations and chromosome 5 gain. Compared to C1, survival was significantly worse in C2 (HR 2.52; 95% CI, 1.37–4.63) and C3 (HR 2.14; 95% CI, 1.17–3.89). We also estimated the proportions of immune cell fractions from the bulk RNA sequencing data using CIBERSORTx and classified TME signatures into the following hierarchical clusters: TME1 (characterized by increased B and TFH cells), TME2 (macrophages), and TME3 (activated mast cells). TME2 was associated with shorter survival (HR 3.4; 95% CI, 1.6–7.5) and was more frequent in C2 (64.3%) than in C1 (7.7%), whereas C1 had more TME3 signatures (80.8% vs. 28.6%). These findings highlight a significant relationship between genetic subtypes and TME signatures in PTCL, with important implications for clinical prognosis.


  • Open Access

    Genetic profiles and clinical features in subcutaneous panniculitis‐like T‐cell lymphomas

    by Yui Okamura, Kenichi Makishima, Yasuhito Suehara, Sakurako Suma, Yoshiaki Abe, Ryota Matsuoka, Tatsuhiro Sakamoto, Keiichiro Hattori, Yasuhisa Yokoyama, Takayasu Kato, et al.

    Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is a rare peripheral T‐cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five‐year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole‐exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5‐year median follow‐up, one patient developed autoimmune‐related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long‐term follow‐up.


  • Open Access

    Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution

    by Sakurako Suma, Yasuhito Suehara, Manabu Fujisawa, Yoshiaki Abe, Keiichiro Hattori, Kenichi Makishima, Tatsuhiro Sakamoto, Aya Sawa, Hiroko Bando, Daisuke Kaji, et al.

    T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.


  • Open Access

    Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization

    by Yoshiaki Abe, Junko Zenkoh, Daisuke Ikeda, Sawa Aya, Daisuke Kaji, Rikako Tabata, Ryota Matsuoka, Manabu Fujisawa, Kenichi Makishima, Sakurako Suma, et al.

    Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H

  • Open Access

    Investigation of Clonal Hematopoiesis in New Japanese Cohort

    by Kenichi Makishima, Kashima Yukie, Yuta Kuze, Sakurako Suma, Yoshiaki Abe, Yasuhito Suehara, Tatsuhiro Sakamoto, Keiichiro Hattori, Sakura Kito, Tran Bich Nguyen, et al.

    Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund

  • Open Access

    S237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA

    by Yasuhito Suehara, Kana Sakamoto, Manabu Fujisawa, Kota Fukumoto, Yoshiaki Abe, Kenichi Makishima, Sakurako Suma, Takeshi Sugio, Koji Kato, Koichi Akashi, et al.

  • Open Access

    Clonal germinal center B cells function as a niche for T-cell lymphoma

    by Manabu Fujisawa, Tran B. Nguyen, Yoshiaki Abe, Yasuhito Suehara, Kota Fukumoto, Sakurako Suma, Kenichi Makishima, Chihiro Kaneko, Yen T.M. Nguyen, Kensuke Usuki, et al.

    Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox × G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre × Tet2flox/flox × G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40–Cd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40–CD40LG axis.


  • Open Access

    Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples

    by Kenichi Makishima, Yasuhito Suehara, Yoshiaki Abe, Keiichiro Hattori, Manabu Kusakabe, Ryota Matsuoka, Shigeru Chiba, Mamiko Sakata‐Yanagimoto